Navigation Links
EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Date:10/12/2009

VIENNA, Austria, October 12 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Bhupinder Hundle, PhD, to the newly created position of Senior Vice President Marketing & Sales. Dr. Hundle will be responsible for the worldwide sales of EUCODIS Bioscience' products. In 2009 the Company has started bringing to market its own enzymes portfolio. The Company had previously established its technology and its enzyme development expertise in commercial collaborations with industry partners.

"We are excited about the wealth of experience that Bhupinder brings on board in establishing and leading an effective sales force", said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "At EUCODIS Bioscience Bhupinder will be responsible for building the sales structure that optimally serves our target industries in Europe, the US, and Asia."

"I am proud to join a biotechnology company like EUCODIS Bioscience, with its proven capabilities in developing and bringing industrial enzymes to the market", commented Dr. Bhupinder Hundle. "With its industry experience and its powerful technology, EUCODIS Bioscience has the potential to become a key enabler of white biotechnology applications, both in established industries and in future technologies such as the generation of fine chemicals from biomass."

Dr. Hundle comes to EUCODIS Bioscience from Lonza, Switzerland, where he headed the sales team for the Lonza Cell Discovery product range in UK, Ireland, the Netherlands, and Northern Europe. Prior to joining Lonza Bhupinder served as European Sales Director for Amaxa AG for 6 years. He has more than 10 years of experience in working with B2B customers in the pharmaceutical and biotechnology industries in Europe and the US.

Dr. Hundle has a B.Sc. (Hons) degree in Molecular Biology, an M.Sc. degree in Medicinal Chemistry from Loughborough University, UK, and received his PhD degree in Biochemistry from Simon Fraser University, British Columbia, Canada. He worked as a postdoctoral fellow at Chemical Biodynamics Laboratory, Chemistry Department, University of California, Berkeley and as a Senior Research Fellow at University of California, San Francisco.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
5. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
6. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
7. Neurocrine Biosciences Presents Elagolix Data
8. Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
9. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
10. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
11. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):